Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Potential New Drug for Inflammatory Bowel Disease

Published: Monday, September 02, 2013
Last Updated: Monday, September 02, 2013
Bookmark and Share
Vedolizumab, a new intravenous antibody medication, has shown positive results for treating both Crohn's disease and ulcerative colitis.

The findings, published in two papers, will appear in the August 22 issue of the New England Journal of Medicine (NEJM).

Dr. William Sandborn, MD, principal investigator of the Crohn's disease study, said the results offer new hope to the more than one million Americans who suffer from inflammatory bowel disease (IBD) and do not respond to treatment. Both studies showed that the use of vedolizumab resulted in remission and discontinued use of prednisone, a common yet difficult to tolerate drug used to treat both diseases.

"The two trials showed highly encouraging results for patients suffering from moderate-to-severe Crohn's disease and ulcerative colitis when conventional therapy such as steroids, immune suppressive drugs and anti-tumor necrosis factor (TNF) biologic drugs failed," said Sandborn, of the Division of Gastroenterology at UC San Diego School of Medicine and director of the Inflammatory Bowel Disease Center at UC San Diego Health System. "This is a disease modifying drug. In many cases of patients with ulcerative colitis, complete healing of the bowel was observed and maintained with continued use of vedolizumab."

Vedolizumab is targeted to disease within the digestive tract so other areas of the body remain unaffected. It blocks immune system cells that release proteins called cytokines that trigger inflammation, causing tissue damage and diarrhea to move into the small intestine and colon. The targeted nature of the medication helps reduce troublesome side effects such as weight gain, nausea and headaches caused by other treatment options. Current treatments such as steroids and immunosuppressive medications broadly suppress the immune system, which can also put the patient at risk for infections.

"Inflammatory bowel disease causes severe ongoing bouts of illness that adversely affect a patient's quality of life at home and work," said Sandborn. "These latest findings will potentially lead to a new drug therapy that will improve a patient's overall lifestyle."

Crohn's disease and ulcerative colitis are forms of inflammatory autoimmune diseases, impacting the small intestine and colon. Clinical symptoms include abdominal pain, diarrhea, intestinal bleeding, fecal urgency and weight loss. Serious complications such as bowel obstruction, colon cancer, malnutrition and abscesses can also occur, resulting in hospitalization and the possible surgical removal of portions of the bowel and colon.

Eight hundred and ninety five patients were part of the ulcerative colitis trial conducted in 34 countries, and 1,115 patients were part of the Crohn's disease clinical trial conducted in 39 countries. Eligible patients for both trials were between 18 and 80-years-old and were treated for 52 weeks in the placebo-controlled studies. Benefits could be seen six weeks into the study.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Opening the Door to Safer, More Precise Cancer Therapies
New method regulates when, and how strongly, cancer-killing therapeutic T cells are activated.
Tuesday, September 29, 2015
Nanosponge Vaccine Fights MRSA Toxins
Nanosponges that soak up a dangerous pore-forming toxin produced by MRSA could serve as a safe and effective vaccine against this toxin.
Wednesday, December 04, 2013
Study Finds Potential Medical Uses for Algae
Can scientists rid malaria from the Third World by simply feeding algae genetically engineered with a vaccine?
Monday, April 22, 2013
FDA Names Breast Cancer Drug a Breakthrough Therapy
An experimental drug being investigated for the treatment of advanced breast cancer by researchers at UCLA this week received breakthrough therapy designation from the U.S. FDA.
Monday, April 15, 2013
Antimalarial Drug Launched
Twelve years after a breakthrough discovery in his UC Berkeley laboratory, professor of chemical engineering Jay Keasling is seeing his dream come true.
Friday, April 12, 2013
Engineered Small-Pox Vaccine may Kill Liver Cancer
As part of a multicenter clinical trial, researchers at University of California are evaluating Pexa-Vec (JX-594) to slow the progression of hepatocellular carcinoma (HCC) or liver cancer.
Thursday, April 11, 2013
Immune Cells Cluster and Communicate ‘Like Bees,’ Researcher Says
UCSF study on T-cell behavior sheds light on how vaccines work.
Tuesday, March 19, 2013
Biologists Engineer Algae to Make Complex Anti-Cancer ‘Designer’ Drug
Biologists at UC San Diego have succeeded in genetically engineering algae to produce a complex and expensive human therapeutic drug used to treat cancer.
Thursday, December 13, 2012
Strengthening Proteins with Polymers
Researchers describe how they synthesized polymers to attach to proteins in order to stabilize them during shipping, storage and other activities.
Tuesday, May 22, 2012
Scientific News
Boosting Breast Cancer Treatment
To more efficiently treat breast cancer, scientists have been researching molecules that selectively bind to cancer cells and deliver a substance that can kill the tumor cells, for several years.
"Good" Mozzie Virus Might Hold Key to Fighting Human Disease
Australian scientists have discovered a new virus carried by one of the country’s most common pest mosquitoes.
World’s First Therapeutic Venom Database
Open-source library describes nearly 43,000 effects on the human body.
Speeding Up the Process of Making Vaccines
System uses a freeze-dry concept to develop "just-add-water" solution.
Surprising Trait Found in Anti-HIV Antibodies
Scientists at The Scripps Research Institute (TSRI) have new weapons in the fight against HIV.
New Method Identifies Up to Twice as Many Proteins and Peptides
An international team of researchers developed a method that identifies up to twice as many proteins and peptides in mass spectrometry data than conventional approaches.
The Do’s and Don’ts of SPR Experiments
Surface Plasmon Resonance (SPR) is a technique that is becoming more widely used, particularly by anyone who wants to obtain accurate on (association) and off (dissociation) rates for biomolecular binding.
Genetically Engineering Algae to Kill Cancer Cells
New interdisciplinary research has revealed the frontline role tiny algae could play in the battle against cancer, through the innovative use of nanotechnology.
Novel Stem Cell Line Avoids Risk of Introducing Transplanted Tumors
Progenitor cells might eventually be used to repair or rebuild damaged or destroyed organs.
Single Vaccine for Chikungunya, Related Viruses May be Possible
What if a single vaccine could protect people from infection by many different viruses? That concept is a step closer to reality.

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos